Document is current
Any future updates will be listed below
-
Authors
Levin, Helena
Lybeck, Anna
Frigyesi, Attila
Arctaedius, Isabelle
Thorgeirsdóttir, Bergthóra
Annborn, Martin
Moseby-Knappe, Marion
Nielsen, Niklas
Cronberg, Tobias
Ashton, Nicholas J.
Zetterberg, Henrik
Blennow, Kaj
Friberg, Hans
Mattsson-Carlgren, Niklas
-
Funding
Funding for this research was provided by:
Government funding of clinical research within the Swedish National Health Services
Regional research support, Region Skane
Hans-Gabriel och Alice Trolle-Wachtmeisters stiftelse för medicinsk forskning
Biobanking and BioMolecular resources Research Infrastructure
Lund University
- License Information
-
More Information
Article History
Received: 11 November 2022
Accepted: 12 February 2023
First Online: 24 February 2023
Declarations
:
: Ethics approval was granted by the Regional Ethical Review Board in Lund, Sweden (registration no. 2014-47 and 2022-02681-01). Written informed consent was obtained from patients who regained mental capacity.
: Not applicable.
: HZ has served on scientific advisory boards and as a consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, reMYND, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/ Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other authors declare that they have no conflicts of interest.
